Late-Breaking Data and Clinician Reviews on Now FDA-cleared T2Bacteria Panel Underscore Sepsis Prevention Opportunities at ASM Microbe 2018

LEXINGTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today late-breaker posters and data presented at the American Society for Microbiology (ASM) Microbe conference on June 7-11 that demonstrate the T2Bacteria® Panel’s accuracy and speed, which may enable more rapid treatment of patients with bloodstream infections in order to prevent sepsis. FDA clearance of the T2Bacteria Panel was announced on May 29, 2018, making the T2Bacteria Panel the first and only FDA-cleared test to identify sepsis-causing bacteria directly from whole blood.  …


Leave a Reply

Your email address will not be published.